Testing outcomes after donor CHIP in stem cell transplant
Part of Blood & lymphatic clinical trials.
This study looks at how a genetic risk factor in a stem cell donor (called CHIP) may affect outcomes after an allogeneic (donor-to-recipient) stem cell transplant. It may help doctors better predict which donor factors are important for patient outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- You must be a donor and/or recipient of an allogeneic stem cell transplant (a transplant from another person).
- If you’re in a past-records portion of the study, you previously signed consent to: share clinical data, share leftover/archive samples for genetic testing, and allow storage and future use of those samples.
- You are not eligible if this is an autologous transplant, meaning using your own stem cells (for donor cases meant for self-transplant).
- The study must be using you in a CHIP/donor-outcome context as part of the donor-recipient transplant group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
This study looks at immune cells in your blood and in tissues affected by chronic graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant. By analyzing samples, researchers hope to better understand this condition and improve future treatments.
Hear when a new Clonal Hematopoiesis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.